Screener
Acadia Pharmaceuticals ACAD Ratios & Valuation
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 91.1%-0.8pp | 91.5%-0.6pp | 91.7%+0.2pp | 91.9%+0.3pp | 92%+0.2pp | |
| Operating margin | 7.6%-15.7pp | 7.4%-16.2pp | 9.8%-14.3pp | 23%— | 23.2%— | |
| Net margin | 33.4%+11.6pp | 34.3%+11.3pp | 36.5%+12.8pp | 24.9%+11.1pp | 21.8%+18.4pp | |
| Returns | ||||||
| Return on equity | 35.7%+2.6pp | 37.3%+0.1pp | 39.9%+1.0pp | 35%+7.6pp | 33.2%+26.5pp | |
| Return on invested capital | 10.7%-27.8pp | 10%-34.0pp | 13.4%-39.5pp | 38.8%— | 38.4%— | |
| Efficiency | ||||||
| Asset turnover | 0.8×-0.2× | 0.8×-0.2× | 0.8×-0.2× | 0.9×-0.2× | 1×-0.2× | |
| Liquidity | ||||||
| Current ratio | 3.4×+0.5× | 3.6×+0.7× | 3.8×+1.5× | 3×+0.7× | 2.9×+0.8× | |
| Leverage | ||||||
| Debt-to-equity | 0.1×0.0× | 0×0.0× | 0×0.0× | 0.1×0.0× | 0.1×0.0× | |
| Net debt / EBITDA | -3.2×-2.4× | -2.5×-1.8× | -1.1×0.0× | -0.8×— | -0.8×— | |
| Per Share | ||||||
| Book value per share | $7.56+55.0% | $7.23+58.3% | $7.22+64.0% | $5.38+54.8% | $4.88+56.8% | |
| Valuation | ||||||
| Market capitalization | $4.9B+23.1% | $3.8B+37.0% | $4.52B+48.0% | $3.6B+41.1% | $3.75B+39.7% | |
| Price / earnings | 12.9×-5.0× | 10.1×-2.0× | 11.6×-1.9× | 13.8×-6.1× | 16.9×-71.0× | |
| Price / sales | 4.3×+0.4× | 3.5×+0.7× | 4.2×+1.0× | 3.4×+0.7× | 3.7×+0.7× | |
| Price / book | 3.8×-1.1× | 3×-0.6× | 3.7×-0.5× | 3.9×-0.5× | 4.6×-0.6× | |
| EV / EBITDA | 46.7×+31.5× | 38.4×+27.9× | 37.7×+26.4× | 13.3×— | 14.2×— |
FAQ
- What are Acadia Pharmaceuticals's profit margins?
- Acadia Pharmaceuticals (ACAD) runs a 91.1% gross margin and a 7.6% operating margin, with a 33.4% net margin.
- Where do Acadia Pharmaceuticals's ratios come from?
- Every ratio is computed from Acadia Pharmaceuticals's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
